tiprankstipranks

Boston Scientific initiated with an Outperform at Leerink

Leerink analyst Mike Kratky initiated coverage of Boston Scientific (BSX) with an Outperform rating and $118 price target The firm notes Boston Scientific’s top-tier, double digit topline and EPS growth profile and impressive track record of commercial execution have helped make it one of the most well-regarded companies in the MedTech space. The stock has also been a juggernaut over the past decade and seemingly remains a consensus long, Leerink adds. Despite already lofty expectations, the firm’s deep-dive analysis on the atrial fibrillation market points to FARAPULSE and WATCHMAN likely driving further upside for the company. Additionally, Boston Scientific’s commitment to investing in innovation through accretive M&A over the past few years should help support its durable above-market growth on a longer-term basis, in Leerink’s view.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1